Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
eli lilly
3
×
fda
life sciences
national blog main
abbvie
allergan
amgen
boston top stories
indiana blog main
indiana top stories
national top stories
raleigh-durham blog main
raleigh-durham top stories
10x genomics
alkermes
alprazolam
anemia
antibiotic
astrazeneca
autism
autism spectrum disorder
avexis
biogen
boulder/denver blog main
boulder/denver top stories
brian kaspar
bristol-myers squibb
buprenorphine
cadent therapeutics
cariprazine
celgene
centers for disease control and prevention
cgrp inhibitors
chinook therapeutics
chronic migraine
clostridium difficile
colucid pharmaceuticals
What
fda
won
drug
acute
addresses
alkermes
antipsychotic
approval
august
benefits
bio
biotech
busy
causes
caveats
commonly
condition
days
decades
decisions
designed
devices
drugs
effect
eli
favor
friday
gain
giant
giving
lasmiditan
legacy
lilly
lilly’s
medication
medicine
migraine
new
news
nods
Language
unset
3
×
Current search:
won���t
×
unset
×
" eli lilly "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More